Biogen

The biotech company’s decision to put down roots in Luterbach in the Canton of Solothurn has resonated throughout Switzerland. The Alzheimer’s drug Leqembi has been produced in Luterbach since 2023 and exported worldwide.

Due to the favourable conditions for companies and workers, the Canton of Solothurn was the ideal location for the biotech company Biogen. Construction started in 2016 and the Alzheimer’s drug Leqembi has been produced at the Luterbach site in the Canton of Solothurn since 2023.

Also at the beginning of 2016, Biogen held the groundbreaking ceremony for a state-of-the-art biopharmaceutical production facility in Luterbach in the Canton of Solothurn. ‘The plant in Luterbach will play a key role in Biogen’s strategy to build a forward-looking global supply network for pharmaceuticals. We want our patients to have reliable access to the medicines they need, any time, anywhere,’ said John Cox, Biogen’s Executive Vice President, Pharmaceutical Operations & Technology and Global Therapeutic Operations at the media conference.

‘Switzerland is an ideal location for first-class innovations such as this new plant in the Canton of Solothurn’, stated Swiss Federal President Johann Schneider-Ammann. A number of favourable location factors were decisive for Biogen’s decision to locate its new manufacturing facility in Switzerland: qualified employees, an excellent education system, proximity to Biogen’s international headquarters in Zug, synergies with existing manufacturing activities in the region and a favourable business environment.